人免疫重建SCID小鼠的研究

４２只不渗漏ＳＣＩＤ小鼠分别腹腔注射经冷冻、复苏的胎肝或胎肝加胎胸腺细胞,每鼠２×１０７活细胞,建立人胎肝细胞ＳＣＩＤ小鼠模型Ⅰ和Ⅱ,研究人免疫系统。用人肝癌细胞（ＨＨＣＣ）免疫,ＳＣＩＤ鼠出现初始免疫答应,血清人ＩｇＧ平均滴度分别达到５１３．０±８４．２ｎｇ／ｍｌ和７１９．７±２０１．６ｎｇ／ｍｌ,ＩｇＧ峰值分别出现在免疫重建后１０～１２和１０～１４周,特异性抗ＨＨＣＣ抗体滴度分别达到１∶７０．４±３５．０５和１∶２９４．４±１６８．５２,免疫重建后７～８周龄,ＡＢＣ法免疫组化染色,免疫鼠模型肝、脾中可检出标记人的ＣＤ３＋、ＣＤ２０＋Ｔ和Ｂ淋巴细胞克隆和细胞岛。流式细胞仪检测了抗原免疫组和模型组外周血、脾脏、肝脏的人ＣＤ３＋、ＣＤ４＋、ＣＤ８＋、ＣＤ１９＋、ＣＤ２０＋标记的淋巴细胞数,其中标记ＣＤ２０＋淋巴细胞平均值外周血３．１２±３．０３％、脾脏１．４±０．２０％、肝脏２．３２±１．４９％。而无抗原免疫的模型组在肝脏仅有微量或检测不到人标记淋巴细胞。     

国产重组酵母乙型肝炎疫苗接种小学生的3年免疫效果观察

本文报告对２５８ 名小学生应用０、１、６ 月程序,接种２ 批国产酵母疫苗（５ μｇ／０．５ ｍ ｌ）,１ 批Ａｍ ｇｅｎ 酵母疫苗（１０ μｇ／ｍ ｌ）,１ 批Ｍ ＳＤ 酵母疫苗（５ μｇ／０．５ ｍ ｌ）的小学生免后３ 年（（Ｔ３６）效果观察。结果表明,Ｔ３６ 时抗体 ＧＭＴ（几何平均滴度）,Ａｍ ｇｅｎ 疫苗组（１４５．７５）显著高于 ２ 批国产疫苗（９２．１１、８３．５２）和Ｍ．Ｓ．Ｄ 苗组（７４．６２）,抗体ＧＭＴ 峰值显著低于Ａｍ ｇｅｎ 和Ｍ ．Ｓ．Ｄ 苗的２ 批国产酵母疫苗,与Ｍ．Ｓ．Ｄ 苗抗体ＧＭＴ 水平无显著差异（Ｐ＞ ０．０５）。抗体阳转率间各疫苗组均无显著差异（９３．１０％ ～７４．１４％ ）。本次随访结果表明,采用０,１,６ 免疫程序,国产酵母疫苗免后３ 年的抗体阳转率和抗体ＧＭＴ水平不低于进口同类酵母疫苗的水平。     

麻疹活疫苗两剂免疫程序述评

概述了全球采用麻疹活疫苗两剂免疫程序的现状，对其效果、效益进行了初步分析。笔者参照国内外资料，结合我国现阶段麻疹流行病学特征（特别是年龄分布）及现行麻苗接种程序进行了讨论。认为把我国现行程序中７岁时的麻苗复种，提前至１２～１５月龄，将对降低学龄前儿童和学龄人口的麻疹发病率及死亡率起到重大作用。笔者提出的麻苗接种程序为：在我国大多数地区，实行８月龄初种，１２～１５月龄复种；至７岁时，查验麻苗接种记录（或证明），对未接种或接种史不明（且未患麻疹）者进行补种。在麻疹高发或高危地区，初种年龄可降至６月龄，长大至８～９月龄及时进行复种。     

流行性出血热免疫球蛋白的研制

本文首次报告采用纯化灭活流行性出血热（ＥＨＦ）Ⅰ型疫苗免疫健康献血员,采集ＥＨＦ抗体高滴度的血浆,用低温乙醇法及盐析法分离纯化三批ＥＨＦ免疫球蛋白。结果表明：（１）采用０,１,３,４（月）或０,１,４,５（月）免疫程序,疫苗剂量１～２ｍｌ（０．１５～０．３０ｍｇ蛋白）,受免献血员血清平均抗体滴度可达１∶４０６（ＥＬＩＳＡ）或１∶１１２（ＲＰＨＩ）。（２）通过生化检定,三批制品的电泳纯度为９７．０５％,９６．８４％,９９．２６％;ＩｇＧ单体和二聚体含量为８９．５５％,９１．３０％和９８．２１％。（３）用空斑抑制中和试验及免疫印染试验证明所纯化的免疫球蛋白具有抗ＥＨＦ病毒特异性。（４）三批ＥＨＦ免疫球蛋白的效价测定,结果为ＥＬＩＳＡ滴度≥１∶５１２,ＲＰＨＩ滴度≥１∶１０２４,ＰＲＮＴ（中和抗体）滴度１∶４０。按１６％蛋白计,ＥＨＦ免疫球蛋白的效价可达原料血浆的１０倍以上。（５）无菌、安全、毒性及热原质试验检定结果,全部通过《中国生物制品规程》要求。     

用ELISA法检测2.5S鼠神经生长因子

鼠颌下腺提纯的２５ＳＮＧＦ免疫家兔,获得兔抗ＮＧＦ抗体,研制出鼠２５ＳＮＧＦＥＬＩＳＡ检测试剂盒,该试剂盒灵敏度小于１ｎｇ／ｍｌ,在６７０～０８４ｎｇ／ｍｌ范围内,线性良好,ｒ＝０９９。与大鼠、小鼠及人血浆无非特异反应,在大鼠血浆中,ＮＧＦ样品回收率在９１％～１０７％之间,变异系数小于１０％（ｎ＝４）。结果表明：本试剂盒操作简便,灵敏度高,特异性强,适合药代动力学研究及生产过程中的ＮＧＦ检测。     

儿童麻疹初免时间的探索研究

通过对不同月龄儿童母传抗体衰减规律以及接种成功率的研究,论证麻疹初免时间提前的必要性与可能性,以及提前多少为合适,为进一步的科学决策提供依据。2004年7月至2005年6月,从鹰潭市疾病控制中心预防接种门诊部随机抽取5～8月龄未注射麻疹疫苗的婴儿各100名,检测其麻疹抗体的滴度,研究婴儿麻疹抗体衰减的规律,然后给受检婴儿接种麻疹疫苗0.5ml。初免一个月以后再检测婴儿体内的抗体滴度,研究婴儿对麻疹疫苗的免疫应答与月龄大小的关系,以及与初免前抗体的关系。结果认为儿童麻疹的初免时间应提前到6月龄为宜。     

乙肝疫苗快速阻断HBV母婴传播的研究

为获得更快速的免疫应答,用３０μｇ／ｍｌ乙肝血源疫苗以０、２、６周免疫程序对６８名ＨＢｓＡｇ阳性母亲婴儿作了阻断ＨＢＶ母婴传播免疫效果的观察,并和常规的０、１、６月接种方案的结果进行了比较。结果表明ＨＢＩＧ合并乙肝疫苗或单用疫苗组产生抗─ＨＢｓ（＞１０ｍＩＵ／ｍｌ）血清转换率于Ｔ６Ｍ、Ｔ１２Ｍ时分别为９１．８９％,和８３．８７％;８１．０８％和８３．８７％。短程和常规免疫方案婴儿所产生的保护性抗─ＨＢＳ动态比较,表明以０、２、６周免疫后的Ｔ６ｗ、Ｔ６ｍ时的抗─ＨＢｓ有效率分别为１９．３５％和８３．８７％,明显高于０、１、６月免疫者同期抗体水平（Ｐ＜０．０１）。至Ｔ１２Ｍ时两组的阳转率无显著性差异,说明０、２、６周免疫方案能早期诱导出保护性抗─ＨＢｓ免疫应答。     

对366份拟诊病毒性心肌炎病人血清的CBV抗体测定

采用ＥＬＩＳＡ法对３６６份临床拟诊为病毒性心肌炎患者的血清标本进行了柯萨奇Ｂ组病毒ＩｇＧ抗体的测定,结果为１８６份标本为阳性,检出率为５０８％,其中Ｂ１～Ｂ６型交叉阳性率为６９９％（１３０人次）,单一型阳性率为３０１％（５６人次）。在５０８％的交叉感染阳性标本中以Ｂ４型（９６人次）,Ｂ３型（８６人次）占多数分别为２２８％和２０５％,其次为Ｂ２型、Ｂ５型和Ｂ６型;Ｂ１型较少见,占１０２％,这对病毒性心肌炎的鉴别诊断和流行病学调查具有重要意义。     

尿激酶型纤溶酶原激活剂单克隆抗体的生产及其在抗原纯化中的应用

从ＣＨＯ工程细胞培养上清初步纯化的ｕＰＡ免疫ＢＡＬＢ／ｃ小鼠,通过杂交瘤技术制备单克隆抗体细胞株,取其中一株３８－１－７株作高密度大量培养,细胞密度达１３．２×１０６／ｍＬ时,抗体滴度为１∶６１．４４×１０４。用自制的ｕＰＡ－Ｓｅｐｈａｒｏｓｅ４Ｂ柱纯化抗体。抗体滴度提高２４３倍。纯化后的抗体与活化的Ｓｅｐｈａｒｏｓｅ４Ｂ珠交联,制成ＩｇＧ－Ｓｅｐｈａｒｏｓｅ４Ｂ亲和层析抗体柱,亲和力常数：１．２８×１０９（ｍｏｌ／Ｌ）－１,交联率：８３．５％。直接从培养上清纯化ｕＰＡ,纯度为９６．３％,回收率：８１．６％±１９,纯化倍数：５０倍左右,比活１．１１±０．２９×１０５。试验结果表明该法效果好,方法简单、操作方便、值得进一步研究和应用。     

抗人α2a型基因工程干扰素单克隆抗体及亲和层析柱的研制

应用鼠－鼠杂交瘤细胞技术建立了三系稳定分泌抗重组人α２ａ型干扰素（ｒＨｕ－ＩＦＮ－α２ａ）单克隆抗体细胞系１Ａ５、１Ｂ５和２７Ａ７。细胞连续传代和在液氮中冻存后复苏,分泌抗体能力不变,并且维持在较高水平,细胞培养上清效价１∶２５６～１∶４０９６,腹水１∶２６×１０５～１∶２７×１０８。Ｉｇ亚类测定,１Ａ５和１Ｂ５ＭｃＡｂ为ＩｇＧ１,２７Ａ７为ＩｇＧ２ａ。三系ＭｃＡｂ均识别ｒＨｕ－ＩＦＮ－α２ａ和－α２ｂ,与ｒＨｕ－ＩＦＮ－α１和正常大肠菌体裂解液无反应。竞争ＥＬＩＳＡ试验,三系ＭｃＡｂ分别针对ｒＨｕ－ＩＦＮ－α２ａ上三个不同表位。同ＭｃＡｂ建立双抗体夹心ＥＬＩＳＡ对ｒＨｕ－ＩＦＮ－α２ａ和－α２ｂ均可检测到１５０ｐｇ／ｍｌ,约１０ＩＵ／ｍｌ的敏感度。用提纯的单抗制备亲和层析柱,单抗偶联率９５％以上。三系单抗亲和层析柱均可将粗制ｒＨｕ－ＩＦＮ－α２ａ提纯到９７％以上纯度。平均回收率为：１Ａ５单抗柱９０２％,１Ｂ５单抗柱９５３％,２７Ａ７单抗柱９４７％。比活性平均值依次为１９４×１０８ＩＵ／ｍｇ,１９７×１０８ＩＵ／ｍｇ和１６４×１０８ＩＵ／ｍｇ,残余鼠ＩｇＧ量均符合规程要求。纯化ｒＨｕ－ＩＦＮ?     

梅州市两次麻疹疫苗强化免疫效果分析

目的综合评估分析梅州市两次麻疹疫苗强化免疫效果,为消除麻疹提供科学依据。方法综合分析麻疹疫苗强化免疫现场调查资料、评估法定传染病报告系统中麻疹发病率的变化;随机对辖区内1～12岁健康儿童216名,采用酶联免疫吸附试验(ELISA)进行强化免疫前及完成二次强化免疫后麻疹lgG抗体水平监测。结果监测人群完成二次强化免疫后麻疹IgG抗体阳性率达100.00%(216/216),2009年强化组、2010年强化组麻疹IgG抗体保护率和几何平均滴度(GMT)分别为82.08%、87.62%和1958.83、2050.26,均显著高于强化免疫前;2009年强化免疫后麻疹年发病率由强化免疫前五年平均发病率1.71/10万下降至0.22/10万,下降率87.13%,2010年强化后麻疹年发病率再次下降(0.039/10万),下降率82.27%。结论梅州市两次麻疹疫苗强化免疫效果显著,均大幅度降低了麻疹发病率、提高了人群麻疹抗体水平。     

Wistar大鼠皮内免疫Sabin株脊髓灰质炎灭活疫苗的免疫持久性及加强免疫效果研究

脊髓灰质炎野毒株消灭后,口服脊髓灰质炎减毒活疫苗(Oral polio vaccine,OPV)将被停止使用,脊髓灰质炎灭活疫苗(Inactivated poliovirus vaccine,IPV)将全面替代OPV,但IPV成本过高,难以满足全球需要。皮内免疫可以降低Sabin株脊髓灰质炎灭活疫苗(Inactivated poliovirus vaccine derived from Sabin strain,sIPV)的免疫剂量,本研究将观察sIPV疫苗皮内免疫大鼠后的免疫持久性及加强免疫效果。本研究采用sIPV,设皮内免疫组、全剂量肌肉免疫组和皮内免疫阴性对照组,接种Wistar大鼠,于3剂基础免疫程序完成后第1个月、12个月采血;第12个月采血后加强免疫1剂,并于加强免疫1个月后采血。中和试验检测各血清抗脊灰病毒中和抗体效价,评价皮内免疫sIPV的免疫持久性及加强免疫效果。Wistar大鼠3剂基础免疫后1个月,1/5、1/3剂量皮内免疫组与全剂量肌肉免疫组Ⅰ、Ⅱ、Ⅲ型抗体阳转率均达到了100%,各型别中和抗体几何平均滴度(Geometric mean titer,GMT)均远高于1∶8保护水平。基础免疫后12个月,sIPV全剂量组各型阳转率均维持在80%以上,1/10剂量皮内免疫组在50%以上,1/5剂量皮内免疫组维持在70%以上,1/3剂量皮内免疫组维持在80%以上,除1/10剂量组Ⅱ型外其余各组各型别GMT均维持在1∶8以上。加强免疫后1个月,1/5剂量皮内免疫组、1/3剂量皮内免疫组及全剂量组的Ⅰ型、Ⅱ型、Ⅲ型各组中和抗体阳转率均达到100%,并能够诱导产生远高于1∶8的抗体水平。本研究结果显示sIPV疫苗皮内免疫具有良好的免疫持久性及加强免疫效果。     

Swedish experience of two dose vaccination programme aiming at eliminating measles,mumps, and rubella.

In 1982 a two dose regimen was introduced in Sweden for the combined vaccination against measles, mumps, and rubella of children aged 18 months and 12 years. Since 1977 about half of the preschool children were vaccinated against measles annually, and since 1974 about 80% of 12 year old girls were vaccinated against rubella. During the period 1982 to 1985 90-93% of the eligible age cohorts of 18 month old children and 88-91% of the 12 year old children were immunised with the new combined vaccine. A study in 1982 of about 140 18 month old children who were nearly all seronegative before vaccination showed that 96%, 92%, and 99% seroconverted against measles, mumps, and rubella, respectively. A second study was carried out in 1983 of 247 12 year old children, of whom 11% lacked antibodies to measles, 27% to mumps, and 45% to rubella. This showed seroconversion in 82% and 80% against measles and mumps, respectively, and all children seroconverted against rubella. In the latest study in 1985 of 496 12 year olds 9% and 13% were seronegative against measles and mumps before vaccination, and 41% against rubella. Of these, 88% seroconverted to measles and 80% to mumps, and all converted to rubella when sera were tested by the haemolysis in gel method. After a neutralisation test against measles as well all children showed immunity to the disease. A low incidence of measles and declining figures for mumps and rubella were reported in 1984 to 1986. An outbreak of rubella during 1985 affected mainly boys in age cohorts in which only the girls had been vaccinated during the 1970s.     

Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies

Infants younger than age 9 mo do not respond reliably to the live attenuated measles vaccine due the immaturity of their immune system and the presence of maternal Abs that interfere with successful immunization. We evaluated the immune responses elicited by Sindbis virus replicon-based DNA vaccines encoding measles virus (MV) hemagglutinin (H, pMSIN-H) or both hemagglutinin and fusion (F, pMSINH-FdU) glycoproteins in neonatal mice born to naive and measles-immune mothers. Despite the presence of high levels of maternal Abs, neonatal immunization with pMSIN-H induced long-lasting, high-avidity MV plaque reduction neutralization (PRN) Abs, mainly IgG2a, that also inhibited syncytium formation in CD150(+) B95-8 cells. IgG secreting plasma cells were detected in spleen and bone marrow. Newborns vaccinated with pMSINH-FdU elicited PRN titers that surpassed the protective level (200 mIU/ml) but were short-lived, had low syncytium inhibition capacity, and lacked avidity maturation. This vaccine failed to induce significant PRN titers in the presence of placentally transferred Abs. Both pMSIN-H and pMSINH-FdU elicited strong Th1 type cell-mediated immunity, measured by T cell proliferation and IFN-gamma production, that was unaffected by maternal Abs. Newborns responded to measles DNA vaccines with similar or even higher PRN titers and cell-mediated immunity than adult mice. This study is the first demonstration that a Sindbis virus-based measles DNA vaccine can elicit robust MV immunity in neonates bypassing maternal Abs. Such a vaccine could be followed by the current live attenuated MV vaccine in a heterologous prime-boost to protect against measles early in life.     

The control of viral diseases in the developing countries with the use of existing vaccines]

In developing countries, every year about 70 million measles cases occur with 1.5 million deaths, over 200,000 children contract paralytic poliomyelitis, 50 million people get infected with viral B hepatitis causing over 1 million deaths, and several thousand people perish because of yellow fever according to WHO data. At the present time, there are 12 vaccines against viruses: vaccines against German measles and mumps in addition to the above. The universal immunization program (UIP) of WHO targets measles and polio. In 1989, a WHO resolution envisioned a 90% immunization coverage by the year 2000. Measles vaccination is recommended for children aged 9-23 months, since most children have maternal antibodies during the first 3-13 months of age. The Edmonston-Zagreb vaccine provided seroconversion of 92, 96, and 98% for 18 months vs. the 66, 76, and 91% rate of the Schwarz vaccine. In the US, measles incidence increased from 1497 cases in 1983 to 6382 cases in 1988 to over 14,000 cases in 1989, prompting second vaccination in children of school age. The highest incidence of polio was registered in Southeast Asia, although it declined from 1 case/100,000 population in 1975 to .5/100,000 in 1988. Oral poliomyelitis vaccine (OPV) provides protection: there is only 1 case/2.5 million vaccinations. Hepatitis B has infected over 2 billion people. About 300 million are carriers, with a prevalence of 20% in African, Asian, and Pacific region populations. Plasmatic and bioengineered recombinant vaccine type have been used in 30 million people. The first dose is given postnatally, the second at 1-2 months of age, and the 3rd at 1 year of age. Yellow fever vaccine was 50 years old in 1988, yet during 1986-1988 there were 5395 cases with 3172 deaths in Africa and South America. Vaccination provides 90-95% seroconversion, and periodic follow-up vaccinations under UIP could eradicate these infections and their etiologic agents.     

Study of combined vaccination against yellow fever and measles in infants from six to nine months

A study has been carried out in the Ivory Coast to assess the efficacy of a combined vaccine against yellow fever and measles relative to that of each vaccine administered separately. Healthy children aged six to nine months were recruited and divided into two age groups: less than seven months (group I) and more than eight months (group II). In each group, they were randomly assigned to receive either yellow fever vaccine only (A), measles vaccine only (B), or the combined vaccine (C). The serological responses to measles and yellow fever were assessed in 219 initially seronegative children 45 days after immunization. More than 90% of the children developed yellow fever haemagglutination inhibiting antibodies. Neither age nor combination with measles vaccine influenced the responses to yellow fever vaccine. Measles haemagglutinational inhibiting antibodies were found in 97% of the children and the seroconversion rate was influenced neither by age nor by combination with yellow fever vaccine. Younger infants had lower titres of measles antibody. No particular adverse reactions were notified during the follow up. This study shows that combined yellow fever and measles vaccines are immunogenic in infants from the age of six months. Controlling yellow fever in endemic areas and the prevention of measles in young infants may greatly benefit by this combination.     

乙型肝炎血源疫苗皮内接种4年效果观察

为了解乙型肝炎血源疫苗皮内接种的持久效果,选ＨＢｓＡｇ、抗－ＨＢｓ和抗－ＨＢｃ均（－）的９～１１岁儿童１０３名,随机分成４组,分别皮内接种１μｇ×４和３μｇ×４（均按０,１,２,５月程序）和肌肉接种１０μｇ×３和３０μｇ×３（各按０,１,２月程序）。首针后４８月时,１μｇ、３μｇ、１０μｇ和３０μｇ组抗－ＨＢｓ≥１０ｍＩＵ／ｍＩ者各为６９．２％,８０．０％、９２．３％和８１．８％;ＧＭＴ则为１４．５,７９．０,４４．８和７０．９ｍＩＵ／ｍｌ,３μｇ×４皮内免疫的近期和远期效果与肌肉组３０μｇ×３相似,宜于某些人群采用     

郑州市麻疹疫苗强化免疫前后麻疹流行病学特征分析

目的了解郑州市麻疹疫苗强化免疫对疾病流行特征的影响,为消除麻疹采取针对性措施提供科学依据。方法对郑州市麻疹强化免疫活动前后的2010年和2011年麻疹发病情况进行描述性流行病学分析。结果郑州市强化免疫后麻疹病例大幅减少,2011年较2010年病例数减少90%;全年病例散发,无明显季节性高峰出现;病例构成仍以1岁以下儿童和无免疫史者为主;城区发病高于农村。结论此次麻疹强化免疫活动效果明显,致使麻疹发病率显著下降。     

Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine

In this study, we evaluated the potency of a human papillomavirus (HPV) virus-like particle (VLP)-based vaccine at generating HPV type 11 (HPV-11)-specific cellular and humoral immune responses in seronegative women. The vaccine was administered by intramuscular immunizations at months 0, 2, and 6. A fourth immunization was administered to approximately half of the women at month 12. All vaccine recipients had positive HPV-11 VLP-specific lymphoproliferative responses at month 3 following the second immunization (geometric mean lymphoproliferative stimulation index [SI] = 28.4; 95% confidence interval [CI] = 16.9 to 48.0) and HPV-11 VLP-specific antibody titers following the first immunization at month 1 (geometric mean antibody titer = 53.9 milli-Merck units/ml, 95% CI, 34.8 to 83.7). In contrast, lymphoproliferative and antibody titer responses were never detected in the participants who received placebo. Relatively homogeneous lymphoproliferative responses were observed in all vaccinated women. The mean lymphoproliferative SI of the vaccinated group over the first 12 months of the study was 7.6-fold greater than that of the placebo group following the initial immunization. The cellular immune responses generated by VLP immunization were both Th1 and Th2, since peripheral blood mononuclear cells from vaccinees, but not placebo recipients, secreted interleukin 2 (IL-2), IL-5, and gamma interferon (IFN-gamma) in response to in vitro stimulation with HPV-11 VLP. The proliferation-based SI was moderately correlated with IFN-gamma production and significantly correlated with IL-2 production after the third immunization (P = 0.078 and 0.002, respectively). The robust lymphoproliferative responses were specific for HPV-11, since SIs generated against bovine papillomavirus and HPV-16 VLPs were not generally observed and when detected were similar pre- and postimmunization.     

Transplacental measles immunity in infants in the 1st year of life]

A total of 187 parturients (66 with a history of measles and 121 immunized with live measles vaccine, or LMV, in childhood) and their 187 newborn infants, as well as 195 children aged up to 1 year, were examined. Antimeasles antibodies in blood sera were detected in the hemagglutination inhibition test. In all mothers with a history of measles and in their newborn infants antimeasles antibodies in different titers were detected. In mothers, formerly immunized with LMV, antimeasles antibodies were absent in 5.8% and in their newborn infants, in 6.6% of the examinees. Among children aged up to 1 year, born of formerly immunized mothers, more rapid disappearance of passive antimeasles immunity was observed. In cases of contact with measles, the serological examinations of all children born of mothers immunized with LMV should be carried out in order to protect seronegative children by passive or active immunization.